Navid Hafez

Navid Hafez, MD, MPH is an Adjunct Assistant Professor of Medical Oncology at Yale School of Medicine. He specializes in developmental therapeutics and immuno-oncology mechanisms, with a focus on clinical trials for metastatic solid tumors. His academic appointments include roles in the Department of Medical Oncology and Hematology, and he collaborates with the Yale Cancer Center.

Dr. Hafez holds an MD from the University of Wisconsin School of Medicine and Public Health, an MPH from UC Berkeley, and a BS from the University of Wisconsin. His research emphasizes drug resistance mechanisms, novel anticancer agents, and combination therapies in oncology. Key collaborations include work with Patricia LoRusso, Daniel Petrylak, and Michael Hurwitz.

His recent publications (2024-2025) focus on phase I/II clinical trials evaluating drugs like CBX-12, brigimadlin (BI 907828), and adagrasib. These studies explore efficacy/safety in biliary tract cancer, pancreatic cancer, and KRASG12C-mutated tumors. His work also includes bioequivalence studies of niraparib and drug combination strategies.

Dr. Hafez has contributed to translational research in prostate cancer (docetaxel efficacy), bladder cancer (BCG/immune markers), and historical analyses of tobacco marketing tactics. He actively participates in multidisciplinary teams addressing cancer drug development and precision medicine.